The first drug using spherical nucleic acids to be systemically given to humans has been developed by Northwestern University scientists and approved by the FDA as an investigational drug for clinical investigation in the deadly brain cancer glioblastoma multiforme.
Related coverage:
Targeting a Rare Brain Cancer With Spherical Nucleic Acids
Video Mar 11, 2021 | Taken from NorthwesternU, YouTube
Advertisement
Recommended Videos
Like what you just watched? You can find similar content on the communities below.
Biopharma Cancer Research NeuroscienceTo personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free
LOGIN SUBSCRIBE FOR FREE
Advertisement